Article Information
History
- July 24, 2022.
Article Versions
- You are currently viewing Version 1 of this article (July 24, 2022 - 08:24).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Professor Saye H Khoo, FRCP1,2,*,
- Richard FitzGerald, PhD1,3,
- Geoffrey Saunders, MSc4,
- Calley Middleton4,
- Shazaad Ahmed, FRCPath5,
- Professor Christopher J Edwards, MD6,7,
- Dennis Hadjiyiannakis, FRCP8,
- Lauren Walker, PhD1,3,
- Rebecca Lyon, PGCert3,
- Victoria Shaw, PhD9,
- Pavel Mozgunov, PhD10,
- Jimstan Periselneris, PhD11,
- Christie Woods, PGDip3,
- Katie Bullock, MSc12,
- Colin Hale, BSc3,
- Helen Reynolds, MPhil1,
- Nichola Downs, PGCert4,
- Sean Ewings, PhD4,
- Amanda Buadi, MSc6,
- David Cameron, BMBS8,
- Thomas Edwards, PhD13,
- Emma Knox, PhD4,
- I’ah Donovan-Banfield, MRes14,
- Professor William Greenhalf, PhD12,
- Justin Chiong, MBA1,
- Lara Lavelle-Langham, BSc12,
- Michael Jacobs, FRCP16,
- Wendy Painter, MD17,
- Wayne Holman, MD17,
- Professor David G Lalloo, FRCP18,
- Michelle Tetlow, MSc1,
- Professor Julian A Hiscox, PhD14,
- Professor Thomas Jaki, PhD10,19,
- Thomas Fletcher, PhD2,20,
- Professor Gareth Griffiths, PhD4 and
- the AGILE CST-2 Study Group
- 1Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
- 2Tropical and Infectious Disease Unit, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
- 3NIHR Royal Liverpool and Broadgreen Clinical Research, Liverpool University Hospital NHS Foundation Trust, Liverpool, UK
- 4Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
- 5NIHR Manchester Clinical Research Facility, Manchester, University NHS Foundation Trust, Manchester, UK
- 6NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 7Human Development and Health School, University of Southampton, Southampton, UK
- 8NIHR Lancashire Clinical Research Facility, Lancashire Teaching Hospitals NHS Foundation Trust
- 9Clinical Directorate, University of Liverpool, Liverpool, UK
- 10MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
- 11NIHR Kings Clinical Research Facility, King’s College Hospital NHS Foundation Trust, London, UK
- 12Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
- 13Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK
- 14Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
- 15National Institute of Health Research, Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK
- 16Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK
- 17Ridgeback Biotherapeutics, Miami, Florida, USA
- 18Director, Liverpool School of Tropical Medicine, Liverpool, UK
- 19Computational Statistics, University of Regensburg, Regensburg, Germany
- 20Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
- ↵*Correspondence to: Professor S.H. Khoo, Pharmacology and Therapeutics, University of Liverpool, Liverpool L7 8TX, UK khoo{at}liverpool.ac.uk
Posted July 24, 2022.
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
